Chronic Conditions Collide: The Rising Complexity of Long-Term Disability Claims Français
Sun Life data shows many Canadians on disability are living with more than one chronic health condition
TORONTO, June 19, 2025 /CNW/ - The latest report in Sun Life's Designed for Health series reveals a troubling trend in long-term disability (LTD) claims among Canadians. Mental disorders, circulatory disorders and cancer are the top three reasons for LTD, but their claims don't stop there. Employees on disability leave are increasingly struggling with multiple, overlapping health disorders, making their LTD claim more complex.
Multiple chronic conditions (known as "comorbidities" or "multiple morbidities") have become more common among Canadians. Sun Life looked at the drug claims data from over 1.5 million people on LTD and found:
Diabetes, mental disorders and cardiovascular conditions are among the top drug claims to treat a secondary condition.
Members on LTD are two times more likely to claim for a chronic disease drug related to a secondary condition than those not on LTD.
They are three times more likely to claim for chronic disease drugs, treating two or more conditions in addition to their primary LTD claim.
Diabetes is a common thread throughout many LTD claims and illustrates how chronic health conditions are overlapping:
Plan members on LTD leave are almost three times more likely to have a diabetes drug claim than others.
Drug claims for diabetes are up 30% from 2019 to 2023 across all claimants, not just LTD.
"Long-term disability claims are often complex and our data tells us that Canadians, more than ever, are struggling when it comes to their health and well-being," says Marie-Chantal Côté, Senior Vice-President, Sun Life Health. "Dealing with multiple chronic conditions can be challenging and requires a holistic and comprehensive approach to recovery. As a trusted health partner to millions of Canadians and their families, our mission is to empower our members with personalized solutions, ensuring easier access to the care they need."
Supporting Employees on LTD to Return to Work
The presence of two or more health issues often worsens the primary condition and makes disease management more complicated. This can mean a long and difficult road to recovery. Those with comorbidities often see a delay in returning to work and remain on claim for longer than the average claim.
"The road to recovery looks different for everyone. When helping an employee return to health, it's important we look at the full picture of their health, from comorbidities to personal stressors, to come up with a treatment plan that is right for them," says Côté. "We take an empathic approach to care that helps employees regain a sense of normalcy."
Sun Life takes a holistic approach to supporting our plan members. Some of the innovative health solutions we offer include:
Psychosocial Questionnaire – Sun Life's innovative new tool allows case managers to gain a deeper understanding of plan member health. The questionnaire helps identity case complexity and ensures members get the timely, additional support and treatments they need.
Medical Confidence – Through our partnership with Kii Health, Medical Confidence is offered to our members to enhance disability claim support by offering timely access to specialist care, saving plan members an average of 317 wait days for specialist appointments. 1
Pharmacogenomic testing – Allows plan members to find the right drug treatment faster by potentially eliminating or reducing the trial-and-error process of finding the right medication.
Read the 2025 Designed for Health Report to learn more about the trends in long-term disability claims in Canada.
About Sun Life
Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2025, Sun Life had total assets under management of $1.55 trillion. For more information, please visit sunlife.com.
Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.
Note to editors: All figures in Canadian dollars
To contact Sun Life media relations, please email [email protected].
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic ®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile. In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba ®). BEIJING and BRIDGEWATER, N.J., June 21, 2025 /CNW/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions. Bofanglutide injection and GZR4 injection are investigational drugs that have not yet been launched in any country. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Bofanglutide injection: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus (T2DM) In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. After 23 weeks of treatment, the mean HbA1c change from baseline in the bofanglutide groups was -1.81% compared to 0.12% in the placebo group, with an estimated treatment difference of -1.93% points *. The proportion of participants achieving an HbA1c target of <7.0% and ≤6.5% was 57.7% and 46.2%, respectively, compared to zero in the placebo group. In terms of weight management, participants treated with bofanglutide experienced a mean reduction in body weight of 6.92 kg from baseline, corresponding to a 9.3% decrease, compared to a minimal reduction of 1.2% in the placebo group. Furthermore, bofanglutide showed comprehensive improvements over placebo in multiple metabolic parameters, including fasting plasma glucose (FPG), glycated albumin (GA), waist circumference (WC), blood pressure, and lipid profiles. In terms of safety, bofanglutide was well tolerated in patients with T2DM. Consistent with known GLP-1 RAs, the most common adverse events were gastrointestinal-related, primarily observed during the early dose-escalation period with mostly mild to moderate in severity. No hypoglycemic events or investigational product-related serious adverse events were reported during the study. Bofanglutide injection: A Multicenter, Randomized, Open-label, Active comparator-controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of bofanglutide Injection versus Semaglutide (Ozempic ®) in Chinese Patients with T2DM In this Phase 2b clinical trial (NCT06256549), a total of 272 eligible Chinese patients with T2DM, who had inadequate glycemic control either after lifestyle intervention or despite stable use of oral antidiabetic drugs (OADs) for at least 3 months, were randomized to receive bi-weekly (Q2W) 12 mg (N=55), 18 mg (N=54), 24 mg (N=55) bofanglutide injections, or once-weekly (QW) 24 mg (N=54) bofanglutide injections, or 1 mg semaglutide (Ozempic ®, N=54) for 24 weeks of treatment, including the dose-escalation period. The primary endpoint was HbA1c change from baseline to week 24. After 24 weeks of treatment, the mean reductions in HbA1c from baseline were 1.87%, 2.28%, and 1.94% in the bofanglutide groups at 12 mg, 18 mg, and 24 mg Q2W, respectively, and -2.32% in the 24 mg QW group. All these treatment regimens showed greater HbA1c reductions compared to the semaglutide group (-1.60%), with the 18 mg Q2W and 24 mg QW bofanglutide groups demonstrating statistically significant superiority (p<0.001) *. Among drug-naïve patients with inadequate glycemic control despite lifestyle interventions, the 18 mg Q2W bofanglutide group achieved a mean HbA1c reduction of 2.98%, which was significantly greater than that observed with semaglutide (-2.04%; p<0.001)*. The proportions of patients achieving HbA1c target of <7.0% were 63.0% to 73.6% in the Q2W bofanglutide group, 75.0% in the QW bofanglutide group, and 70.0% in the semaglutide group. For the HbA1c ≤6.5% target, the corresponding proportions were 58.2% to 67.9%, 69.2%, and 62.0%, respectively. Furthermore, the mean change in body weight for all bofanglutide groups from baseline to week 24 ranged from -4.26 to -6.54 kg, compared to -3.25 kg in the semaglutide group *. Bofanglutide also greatly improved FPG, blood pressure, lipid profiles, and other metabolic parameters. In this study, bofanglutide was g enerally well tolerated, with safety and tolerability consistent with other known GLP-1 RAs. The most common adverse events were gastrointestinal-related, mostly mild to moderate in severity, and no sever e hypoglycemic events were observed. GZR4 injection: A Multicenter, Randomized, Open-label, Active-controlled, Treat-to-target Phase 2 Clinical Study Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin degludec (IDeg, Tresiba ®) in Chinese patients with T2DM This Phase 2 clinical study (NCT06202079) enrolled a total of 83 Chinese patients with T2DM who had inadequate glycemic control on OADs (Part A), and 96 patients with inadequate control on OADs combined with basal insulin therapy (Part B). Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba ®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment. The primary efficacy endpoint was the change in HbA1c from baseline to week 16. After 16 weeks of treatment, in patients from Part A, the mean change in HbA1c was comparable between GZR4 groups and IDeg groups (−1.50% versus -1.48%, p = 0.90). The proportion of participants achieving HbA1c target of <7.0% was 59.5% in the GZR4 group and 70.7% in the IDeg group, while the proportion achieving HbA1c target of ≤6.5% was 38.1% and 29.3%, respectively. In patients from Part B, GZR4 demonstrated significantly greater HbA1c reduction compared to IDeg (-1.26% vs -0.87%; p<0.01), with a higher proportion of patients achieving HbA1c targets of <7.0% and ≤6.5% (52.1% vs 29.2%; 25.0% vs 10.4%). In addition, improvements from baseline in FPG and time in range (TIR) were comparable between the GZR4 group and IDeg group. GZR4 achieved effective glycemic control without the need for a loading dose at the first administration, while the total weekly insulin dosage (mole) for GZR4 was approximately 40–50% of that for IDeg (p<0.001). In terms of safety, the incidence of adverse events was similar between the two groups. No severe hypoglycemic events or investigational product-related serious adverse events were reported during the study. * The clinical data were presented as mean (SE) value. The detailed results of the above Phase 2 clinical study will be published in a peer-reviewed journal. Conclusion and Future Direction The latest clinical results presented at this year's ADA conference highlight Gan & Lee Pharmaceuticals' leading position in the development of long-acting antidiabetic therapies. Building on these positive outcomes, the company will continue to advance the research and development of innovative treatments for diabetes. Currently, Gan & Lee has initiated and is accelerating large-scale Phase 3 clinical programs in China for bofanglutide injection and GZR4 injections for the treatment of type 2 diabetes, aiming to provide more effective treatment options for patients with diabetes. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin ®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin ®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin ® 30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin ® 30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine ®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine ®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
Winnipeg Free Press
3 hours ago
- Winnipeg Free Press
Fading into the background
Opinion The number of people in Canada experiencing homelessness continues to climb despite increased government funding. This prompted dozens of experts from across the country to gather at a landmark forum convened by the Mental Health Commission of Canada (MHCC) to look for answers to help the 34,000 Canadians who — on any given night — don't have a decent place of their own. The main outcome of this gathering, the new report Housing First: What's Next?, released this week, confirms what we've witnessed firsthand: there are proven and effective approaches to end chronic homelessness. The report asserts that Housing First — a Canadian-made strategy that addresses housing insecurity — is a proven method to effectively keep people stably housed over the long term. As a country, how do we stand by as our neighbours cycle through emergency rooms, shelters, and jails? Why do we settle for high-cost band-aid interventions when a permanent fix is already within reach? It's like searching for reading glasses perched on our head. We can't expect people to recover from mental illness or addiction without the dignity of a door that locks. Securing safe, affordable housing is the crucial first step. It's a moral imperative, and fiscally responsible. The principle is straightforward: offer permanent housing in regular units scattered throughout communities — no strings attached — then deliver tailored supports for mental health, substance misuse, employment, and community integration. Rather than requiring people to 'earn' housing through demonstrated 'good behaviour,' Housing First posits – correctly – that a safe place to live is foundational for recovery. Just as we wouldn't expect someone with pneumonia to get better in the rain, we can't expect someone diagnosed with bipolar disorder or schizophrenia to recover while navigating shelter waitlists. We were both heavily involved in At Home/Chez Soi, a federally funded $110 million project launched by the MHCC, which ran from 2008 to 2013. It found that chronic homelessness could be ended permanently for most people by combining housing with portable support. With decades of experience under our belts, our conviction has not wavered. Like the dozens of experts who participated in the workshop that led to the report, we continue to believe Housing First should be adopted and scaled up as best practice. When people have stable housing and access to community supports, we see measurable results: fewer hospitalizations, reduced emergency room visits, and decreased police interactions. These outcomes help offset the cost of implementing Housing First programs. While other countries have embraced this Canadian best practice — Finland and Norway have nearly eliminated chronic homelessness using a Housing First approach — we're still working to fully realize what we ourselves have pioneered. Despite its proven success, implementing Housing First is hard work. It requires carefully coordinating health, housing, justice, and social services that typically operate in silos. It forces us to confront the uncomfortable reality that our housing market has become the privilege of the few, rather than a basic human right. But these challenges can be overcome. During our national forum, experts agreed that an ever-shifting landscape requires an equally nimble response. Our report serves as a call to action and a road map: we need Housing First programs to follow the At Home/Chez Soi model, while upping the ante by collecting better data, creating culturally appropriate supports, establishing improved workforce training, boosting leadership, and increasing public engagement. Creating more deeply affordable housing is also urgent, encouraging private market and not-for-profit landlords to support individuals and families experiencing chronic homelessness — people who are deserving of equitable access to housing opportunities. Taken together, we know this will transform lives. Ironically, when Housing First works well, you don't see it. People integrate into communities as tenants and neighbours, a refreshing contrast to the increasing visibility of suffering on our streets. We can all contribute to meaningful change. By understanding evidence-based approaches and working within our communities to prioritize and implement them, we create pathways to housing stability. Each of us has a role in fostering communities where everyone has a place to call home. Above all, we must never turn away from suffering, especially knowing the proven remedy is in plain sight. Tim Aubry is Emeritus Professor at the University of Ottawa and Co-Chair of the Canadian Housing First Network, and Jino Distasio, is a professor at the University of Winnipeg.
Winnipeg Free Press
3 hours ago
- Winnipeg Free Press
Unlocking ‘gateway benefit'
Opinion Michelle MacIver didn't hear about the many government benefits available for her son, who has a disability, from a financial institution or a family physician. Rather, she heard about them through word of mouth. 'I was talking to other parents who told me about the DTC (Disability Tax Credit),' says the Portage la Prairie mother of two young boys. That began a multi-year journey of navigating doctor's offices, government websites, social media and various organizations to understand not just how to apply for the credit, but also whether her son would even qualify. 'There is a lot of misinformation — like people on social media telling me my son wouldn't qualify,' she says, noting it took two years before she finally sent the 16-page tax document to Canada Revenue Agency. MacIver's glad she did. Not only does the credit provide more than $3,000 in tax savings annually, provincial and federal, it is also the 'gateway benefit,' she says. It leads to other programs aimed at providing financial support for Canadians with disabilities and their families, such as the Registered Disability Savings Plan (RDSP). Those qualifying for the credit will also be eligible for the new Canada Disability Tax Benefit, which starts next month, paying adults with disabilities up to $200 a month, depending on family net income. While that won't help the MacIver family, given her son is nine years old, it will be a small boost to many Canadians with disabilities. The poverty rate for people with disabilities is about twice the national average, according to Campaign 2000: End Child and Family Poverty. What's more, they face larger costs. The cost of living is estimated to be about 30 per cent higher, given many require additional medical equipment and supportive care, a study from Inclusion Canada found. Federal and provincial disability benefit programs are designed to help address these issues, but many are underused, including the gateway tax credit DTC. A Statistics Canada report estimates most Canadians with disabilities have not received the credit. Take-up among those with the most severe impairments is only about four in 10. Use is estimated at about only about 20 per cent for those with severe disabilities, a little more than 10 per cent for Canadian moderate impairments and less than five per cent for people with mild disabilities. These Canadians are not only missing out tax savings; they are forgoing tens of thousands of government monies to help them save for the future through an RDSP. 'It's not being maximized well at all,' says Sara Kinnear, Winnipeg-based director of tax and estate planning at IG Wealth Management. She points to the low take-up of the RDSP, which provides annual grants and bonds to individuals with disabilities age 49 and younger. Statistics Canada data shows the use rate is about 35 per cent. That likely does not reflect the total number of disabled Canadians missing out because the gateway DTC, necessary to open an RDSP, has a much lower take-up rate. One key reason for the low usage is the complexity involved in being approved for the DTC, says Liss Cairns, program manager with the Plan Institute in Vancouver, a non-profit that supports people with disabilities. Applying for the credit is complicated, requiring a health-care provider to fill out and sign the form to confirm an individual's disability. Many physicians now charge fees in the hundreds of dollars to do so, though Cairns adds new federal funding will help cover those costs. Other challenges include public perception, especially for the RDSP. Another issue is awareness even for individuals, who have the DTC and are eligible to open an RDSP. 'Many think, 'What value is this for me? I can't save anything,'' Cairns says. Even individuals who cannot contribute their own money to an RDSP could be missing out. They may be eligible for the Canada disability savings bond whereby the federal government contributes $1,000 annually to their RDSP to a lifetime maximum of $20,000. Of course, individuals and their families able to contribute to an RDSP are eligible for the Canada disability savings grant. A matching grant, it provides up to $3,500 annually from the feds ($3 of benefit for every $1 contributed) to a lifetime maximum of $70,000. Both the bond and grant are pared back gradually as household net income rises. The bond is eliminated when income exceeds about $56,000, and the matching grant is reduced to $1,000 maximum per year when income exceeds about $111,000. 'Overall, it's a great program, but it's also probably the most complicated registered program,' Kinnear says, noting individuals must be wary of early withdrawals for the plan. Money withdrawn from an RDSP within 10 years of the last grant or bond may be subject to steep penalties, she adds. It's also important to start as soon as possible not only because money in the RDSP can compound tax-free. Grants and bonds can only be received up to age 49 though individuals can contribute to their plan up to age 59. 'The design is really to provide retirement savings for these individuals,' Kinnear says, adding all financial institutions can help set up an RDSP. Another resource is the Plan Institute. MacIver leaned on the organization, which provides free assistance, to access the gateway DTC, which allowed her to open the RDSP for her son. Tuesdays A weekly look at politics close to home and around the world. Today, she is a word-of-mouth advocate, helping other parents of children with disabilities. 'Generally, their response is: 'I had no idea this all existed.'' But they're often elated they do exist. If only these many programs were easier to access. 'We know it can be very complex and overwhelming,' Cairns says. 'But we also see the amazing financial empowerment that this can bring.' Joel Schlesinger is a Winnipeg-based freelance journalist joelschles@
